Introduction
Hyperproliferation is widely associated with dysregulated energy metabolism in order to fuel growth and cytokinesis. Thereby it is linked to variousd iseases such as cancer, [1] autoimmune diseases, [2] and fibrosis. [3] The alterede nergy metabolism of cancerw as first investigated by Otto Warburg in 1924. [4] He observed that cancerc ells perform glycolysis and ferment the thereby generated pyruvatet ol actate irrespective of oxygen availability ( Figure 1B ). This phenomenonw as termeda erobic glycolysis, or the Warburg effect, and yields about 4mol ATPp er mol glucose. [1] Nonmalignant cells fuel pyruvatei nto the tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS) in the presence of oxygen in order to generate approximately 36 mol ATPp er mol absorbed glucose( Figure 1A) . The reason for this adapted metabolism remains am atter of debate (e.g.,s ee Liberti and Locasale [5] ).
Ah igh rate of glycolysis in cancer depends on key glycolytic enzymesa nd proteins, especially the glucose transporters GLUT-1/GLUT-3, hexokinase 2a nd pyruvate kinase 2. [6] The increased absorbance of glucose by overexpression of GLUTs contributed to the development of positron emission tomography using 18 F-labeled 2-deoxy-d-glucose, which is used to visualize tumors within the patient'sb ody. [7] Ta rgeting the first rate-limiting step of glycolysis promises to be an effective strategy to limit glucoses upply.T od ate, 14 dif-ferentG LUT isoformsa re known that are subdivided into three distinct protein classes according to their phylogenic homology (e.g.,s ee Barron et al. [8] ). Each GLUT isoform has au nique tissue distribution and substrate specificity and fulfills aspecific physiological function. TheG LUT isoforms GLUT-1 to -4 (class I) were investigated most intensively,w ith ap articularf ocus on GLUT-1. [9] However,n oG LUT inhibitor has been advanced to clinical studies. [10] This review gives an overview of the most promising GLUT inhibitors that were developed within the last 20 years with aview to the treatment of cancer and other disorders.
Discoveryoft he Most Potent GLUT Inhibitors
The fungal metabolite cytochalasin Bd ecreasedt he glucose supplyo fc ancerc ells, which originally spurred the interesti n Glucose addiction is observed in cancer and other diseases that are associated with hyperproliferation. The development of compounds that restrict glucoses upply and decrease glycolysis hasg reat potentialf or the developmento fn ew therapeutic approaches. Addressing facilitative glucose transporters (GLUTs), which are often upregulated in glucose-dependent cells, is therefore of particulari nterest. This article reviews a selection of potent, isoform-selective GLUT inhibitors and their biological characterization. Potential therapeutic applications of GLUT inhibitors in oncology and other diseases that are linked to glucose addictionare discussed. this mode of action. [11] Cytochalasin Bi nhibited the uptake of [ 14 C]2-deoxy-d-glucose ([ 14 C]2DG) in N1S1-67 cells and its incorporation in lactate with an IC 50 value below 4 mm in an oncompetitivem anner (Figure 2, Ta bles1and 2). [11, 12] In human erythrocytes,c ytochalasin Bi nhibited the uptake of [ 14 C]2DG with an IC 50 value of 0.52 mm. [13] It targets GLUT-1 to -4 but not GLUT-7 (Table 2) . [14] Furthermore, cytochalasin Bi nhibited the growth of murine B16F10 cells with aG I 50 value of about 0.4 mm as determined after four days of treatment (Table 2) . [15] Although cytochalasin Bp otently inhibits actin polymerization, which restricts the therapeutic applicability of the natural product, it is often used as ac ontrol compound in metabolic studies. [16] Sincet he discoveryo fc ytochalasin B, several GLUT inhibitors with varying GLUT isoform selectivity have been described including natural products, non-natural small molecules and peptidea nalogues (e.g.,s ee Granchi et al. [10b] ). However,o nly af ew potent compounds (IC 50 < 1 mm)w ere identified (Figure2,T ables 1a nd 2).
The phenolic WZB117 ( Figure 2 ) inhibits uptake of [ 3 H]2DG in A549 cells with an IC 50 value of approximately 500 nm ( Table 1) and was found to decrease extracellularl actatel evels and the intracellular ATPp ool in A549 cells after 6t o2 4hours of treatment. [17] Proliferation and viability of A549 cellsb ut not of nonmalignant NL20 cells were inhibited by WZB117 with micromolar IC 50 (Table 2 ). [17b] Xenograft studies with A549 cells revealed adecrease in the tumor volume by 70 %after treatment with WZB117 for 70 days (daily intraperitoneal injection, 10 mg kg À1 ). WZB117 inhibits GLUT-1 as shown via [ 3 H]2DG uptake inhibition in red blood cells (which express solely GLUT-1). [17b] Although WZB117 has been used as GLUT-1-selective inhibitor in multiple studies mostly focusing on cancer, [18] it was proposed to inhibit mainly GLUT-4 as determined by GLUT-1-, -3-, and -4-overexpressing HEK293 cells ([ 3 H]2DG uptake, Table 2 ). [12b] Kinetic studies revealed ac ompetitive inhibition of glucoseuptake. [12b] Researchers at IOmet Pharma described ac lass of potent imidazopyridine-derived glucoseu ptake inhibitors (see, e.g., compound 155,F igure 2). Compound 155 inhibits the uptake of [ 3 H]2DG in HEK293 cellst hat stably overexpress hGLUT-1 with an IC 50 value of approximately 30 nm (Table 1 ). [19] The isoform selectivity of 59 derivatives within ac ollection of 385 compounds determined for GLUT-1 to -4 in cHEK293c ells that transiently overexpress hGLUT-1 to -4, respectively,s howed that most compounds are unselective among the four GLUT isoforms( Ta ble 2). Compound 155 reduced lactatee xcretion after 4h treatment with an IC 50 value of about 90 nm (5 mm glucose)a nd 400 nm (17 mm glucose) [19] and induced apoptosis in A459 cells with an IC 50 value of 0.126 mm as determined by meanso fl ive-cell imaging using an uclear stain for cell counting (Table 2 ). [19] To date, biological applications of these GLUT inhibitors have not been reported.
Kapoor et al. reportedp eptidea naloguesG LUT-i1 and GLUT-i2 ( Figure 2) , with glucose uptake inhibitory activity.T he cellular assay that was used monitored ATPd epletion of hGLUT-1and luciferase-transfected CHO-K1c ells in the presence of a mitochondrial complex Ii nhibitor. [20] GLUT-i1 and GLUT-i2 inhibit glycolytic ATPp roduction with IC 50 values of 267 and 140 nm,r espectively ( Table 1 ). [20] GLUT isoforms electivity was determined in the same assay using DLD-1 cells (express mainly GLUT-1) and DLD-1 GLUT1 (À/À)c ells (express mainly GLUT-3)o rC HO cells that weres tably transfected with hGLUT-2o rh GLUT-4. GLUT-i1 and GLUT-i2 preferably inhibit GLUT-1 and GLUT-4 over GLUT-2 and GLUT-3 (Table 2) . [20] GLUT-i1 competes with glucosef or the same binding site as determined in glucosec ompetition experimentsa nd crystal structure analysis with hGLUT-1 (Table 2 ). [20] However,a ni mpact of GLUT-i1 or GLUT-i2onc ancer cell growth has not been described.
Bayer researchers developed 1H-pyrazolo[3,4-d]pyrimidine GLUT inhibitors. [21] Compound 3 (patent:e xample 1) inhibits glucoseu ptake with an IC 50 value of 25 nm in rotenone-treated DLD-1 cells in an assay monitoring ATPp roduction. It competitively inhibits glucoseu ptake by targeting GLUT-1 and GLUT-3 withouti nterfering with GLUT-2 activity.S iebeneichere tal. further characterized compound 3 for its in vitro and in vivo pharmacokinetics. [21b] In addition, Bayer reported the first highly GLUT-1-selective compound based on the N-(1H-pyrazolo-4-yl)quinoline-4-carboxamide scaffold. [22] BAY-876 (IC 50 = 2nm,F igure 2, Ta ble 1) possesses ac lear preference for GLUT-1 over GLUT-2, -3, and -4. It competitively inhibits GLUT-1 (Table 2 ) and shows good in vitro and in vivo properties. [22a] However,B AY-876 did not inhibit the growth of the triple-negative breastc ancer cell lines BT549, MDA-MB-436, and HCC70 at 3 mm as determined by live-cell imaging ( Table 2 ). [ ent ovarian cancer cell lines using an MTT assay and determined ag rowth inhibitory IC 50 value of 60 nm for OVCAR-3 cells (Table 2) , whereas SKOV-3c ells yieldeda nI C 50 value of 188 nm and A2780 cells werer esistant to treatment. [24] Hence, the potency of BAY-876 seems to be cell line dependent.F urthermore, daily treatment with 4.5 mg kg À1 BAY-876 over 2weeks decreased the tumor volumeo fS KOV-3 xenograft modelsb y6 8% (Table 2) . Despite al oss of body weight, the mice showedn om ajor health impairment. [24] BAY-876 selectively inhibitsG LUT-1 in vitro and in vivo. However,c are should be takenw hen selecting an appropriate cell line. BAY-876 has been successfully applied to esophageal squamous cancer cell lines TE-8 andT E-11i nc ombinationw ith cisplatin. [25] Kadmon reported ad ifferent class of glucoseu ptake inhibitors. [26] Example 31 in the corresponding patent (Figure2)i nhibited glycolytic ATPg eneration in HT1080 cells that were treated with oligomycin (inhibitor of mitochondrial complexV; Ta ble 1). It potently inhibits the proliferationo fJurkat (294 nm), MOLT-4( 385 nm), and U937 cells (256 nm)a sm easured after 72 hi nasulforhodamineBassay (Table 2) . [26] Chromopynone-1 ( Figure 2 ) was identified by Waldmann et al. as ap otent GLUT-1/-3 isoform-selective inhibitor.C hro-mopynone-1 was developed from ac hromane-tetrahydropyrimidoneh it class that was identified in ac ell-baseds creen monitoring the uptake of 2DG by enzyme-coupled resazurin detection in HCT116 cells. [27] It inhibits glucose uptake (IC 50 = 414 nm)i naGLUT-1-/-3-selective manner as determinedw ith partial rescue of 2DG uptake inhibition in CHO cells that transiently overexpress hGLUT-1 to -4 (Tables 1a nd 2). Growth of HCT116 cells was inhibited by chromopynone-1 with aG I 50 value of > 25 mm (25 mm glucose) and 3.8 mm (5 mm glucose) and of MIA PaCa-2 cells with aG I 50 value of 2.8 mm (25 mm glucose)a nd 0.6 mm (5 mm glucose)a sd etermined by live-cell imaging ( Table 2) . MIA PaCa-2 cellsd epend more on glucose than HCT116 cells. [28] Waldmann et al. also discoveredp iperazin-2-one-derived inhibitors in the same cell-based assay.T he most active member, glutor (IC 50 = 11 nm,F igure 2, Table 1 ), targets GLUT-1, -2 and-3 ( Table 2 ). [27, 29] Cell line sensitivity was tested using 94 different cell lines using as ulforhodamine Ba ssay for 72 ho fg lutor treatment, and revealed that the nonmalignant cell line IMR-90 and peripheral blood mononucleated cells (PBMCs) wereresistant (IC 50 > 30 mm)t ot reatment with glutor,w hereas nearly half of the malignant cell lines exhibited IC 50 < 100 nm (Table 2 ). [29] The urinary bladder carcinomac ell line UM-UC-3 and MIA PaCa-2 cells were mosts ensitive (IC 50 = 4nm,T able 2). [29] The fact that some cancerc ell lines were resistantt og lutor treatment indicates different susceptibilities, as observedf or BAY-876, which was traced back to the metabolicp henotype of the cells and their potential to switch flexibly betweenaglycolytic and an oxidative phenotype. [29] Furthermore, glutord ecreased glycolytic flux, lactatee xcretion and viability of HCT116 cells to as imilare xtent in monolayer cultures and in spheroids which indicates potential applicability in animal models (Table 2 ). [29] In addition, Waldmann et al. described indomorphan GLUTinhibitors. The most active derivative glupin (IC 50 = 4nm, Figure 2 , Ta ble 1) is am ixed-type inhibitort hat targets GLUT-1 and GLUT-3 (Table2). [30] Furthermore, glupin decreases the glycolytic flux in MDA-MB-231 cells which was confirmed in metabolomic measurements monitoring glycolytic metabolites in MOLT16 cells. [30] The growth of various malignant cell lines was suppressed by glupin (IC 50 (UM-UC-3) = 31 nm;I C 50 (MIA PaCa-2) = 62 nm,T able 2) which was monitored using as ulforhodamine Ba ssay. [30] PBMCsa sw ell as the nonmalignant cell line IMR-90w erer esistant to glupin treatment (IC 50 > 30, Ta ble 2). [30] NV-5440 was recently discovered by Kang et al. while searching for mTORC1-selective compounds in ac ell-basedh ighthroughput screen (Figure 2 ). [31] Ta rget identification approachesu sing aS ILAC (stable isotopel abeling by amino acids in cell culture) assay revealed that GLUT-1 was the major targeto fN V-5440 which could be further confirmedb ym etabolic flux analysis of downstream metabolites within the glycolytic cascade. [31] NV-5440 inhibited the uptake of [ 3 H]2DG with an IC 50 value of 36 nm (Table1)i naG LUT-1-to -4-dependent manner while leaving GLUT-5 unaffected (Table2). Selectivity was determined with stably transfected CHO-K1 (hGLUT-1 to Table 1 . Overview of as election of highly potent glucoseu ptake inhibitors.
Name
Class Assay Cell line IC 50 [nm] cytochalasin B [11] natural product GLUT-i1 [20] GLUT-i2 [20] peptide analogue ATPd epletion [b] CHO-K1, hGLUT-1 [a] luciferase [c] 267 AE 133 140 AE 72
ATPd epletion [b,d] DLD-1 25 BAY-876 [22a] small molecule ATPd epletion [b,d] DLD-1 2 example 31 [26] small molecule ATPd epletion [d,e] HT1080 10-100 chromopynone-1 [27] small molecule 2DG uptake [f] HCT116412 glutor [29] small molecule 2DG uptake [ 
Compound Selectivity
Mode of actionI C 50 /GI 50 viability/growth in vitro Furtherp reclinical data cytochalasin B [11] GLUT-1-4 [14a] non-competi-B 16F10 % 0.4 mm [b] [15] reducedt umorformation in mice at 10 and over 7 [14b] tive [a] [12b] 100 mg kg À1 , [15] inhibitor of actinpolymerization WZB117 [17b] GLUT-4 over competitive [a] A549 10-30 mm, [c] NL20 resistant increased cell sensitivity under hypoxicconditions GLUT-1/3 [12b] [12b] in vitro,7 0% tumorv olume reduction in xenograft models compound n.d. n.d. A549 < 126 nm (5 mm Glc) [d] -155 [19] GLUT-i1 [20] GLUT-1/4 n.d. n.d. co-crystalw ith hGLUT-1 GLUT-i2 [20] over GLUT-2/3 compound 3 [21b] GLUT-1/3 competitive n.d. over GLUT-2 BAY-876 [22a] GLUT-1 over competitive OVCAR-3 60 nm, [e] [24] BT549, MDA-MB-436, HCC70 68 %t umor volume reduction in SKOV-3 GLUT-2/3/4 resistant at 3 mm [d] [23] xenografti nmice after 2weeks( 4.5 mg kg À1 ) [24] example 31 [26] n. [27] over GLUT-2/4 MIA PaCa-2 2.8 mm (25 mm Glc), 0.6 mm (5 mm Glc) [d] glutor [29] GLUT-1-3 n.d. UM-UC-34n m, [f] MIA PaCa-2 4nm, [f] PBMCs and equallyp otent in 2D and 3D cell culture over GLUT-4IMR-90r esistanta t30mm, [f] 94 cell lines tested [f] glupin [30] GLUT-1/3 mixed-type UM-UC-33 2nm, [f] MIA PaCa-2 61 nm, [f] PBMCs and metabolomic measurement confirmedr eduction over GLUT-2/4 inhibitionI MR-90 resistanta t30mm [f] 94 cell lines tested [f] of glycolyticm etabolites in MOLT16 cells NV-5440 [31] GLUT-1- -3) or HEK293-T (hGLUT-4 to -5) cells using an ATPd epletion assay in the presence of rotenone. Control experiments revealed that glucosed epletion is responsible for the selective mTORC1 inhibition, which could be confirmed in vivo. [31] Moreover,i nvivop harmacokinetic data are availablef or NV-5440 and the metabolicallym ore stable derivative NV-6297 ( Figure 2 ). [31] 
GLUT Isoform Selectivity Profiles to Target Cancer
GLUTse xhibit at issue-specific distribution and selective expression in cancer. [8, 32] GLUT-1 is expressed at high levelsi n most cancers, and GLUT-3 is predominantly found in the brain, arguing for the development of GLUT-1-selectivec ompounds. [22a] However,G LUT-3 is also overexpressed in numerous additional cancert ypes (beyond glioblastoma that originates from nervoust issue [32b] )s uch as breast and endometrial cancer, head and neck tumors, colon cancer,p ancreatic cancer, nonsmall cell lung cancera nd thyroid carcinomas. [33] Vander Heiden proposed that targeting GLUT-3 might enlarget he therapeutic window of glucoseu ptake inhibitors, as GLUT-3 is only expressedi nas mallf raction of somaticc ells (mainly neurons), but is overexpressed in many cancers. [6] BAY-876 is selective for GLUT-1, [22a] buti ti su nclear if the GLUT-1 isoform selectivity is necessary or sufficient. Chromopynone-1, glutor and glupin target the isoforms GLUT-1 and GLUT-3 and DLD-1 cells upregulate GLUT-1 and GLUT-3 after 24 ha nd 48 hw hen cultured under hypoglycemic conditions. [29, 30] This adaptation mechanism was mimicked by the treatment with 0.5 mm glutor and 0.5 mm glupin, respectively. [29, 30] GLUT4 mRNA stayed unaltered and GLUT2 mRNA was not detectable in these cells, indicating al ow relevance for this isoform under hypoglycemicc onditions. [29, 30] Similar outcomes were observed previously in glucose-deprived neuronal rat cells and in MCF7 and HeLa cells cultured under reduced (2.5 mm)g lucose concentration. [34] The increased expression of GLUT-3 might be an atural rescue mechanism of neuronal cells to ensure glucose uptake in ah ypoglycemice nvironment. Because GLUT-3 has the highest affinity for glucosea mong the GLUT isoforms (K M (2DG) = 1.4 mm), [35] cells expressing GLUT-3 have an advantage in competing for glucosew ith the surrounding tissue. Hence, aG LUT-1-/-3-selective inhibitor may be necessary in order to completelyb lock the glucose uptake of cancer cells.
However,t his observation might be cell line specific,b ecause ar educed glucosel evel (2 mm glucose) or the treatment of A549 cells with WZB117 increased GLUT1 mRNA after 24 h, but decreased GLUT-1 protein levels after 12, 24, and 48 h. [17b] The authors explained these resultsb yarapid upregulation of GLUT1 mRNA under lowg lucosec onditions, but restricted energy andg lucose supply cannot fuel the biosynthesis of the glycosylated GLUT-1 protein. [17b] Also thyroid cancer cell lines (FTC-133a nd 8305c) increased GLUT-1 protein expression after 48 hi ncubation with 5a nd 2mm glucose, compared with 25 mm glucose. GLUT-3 protein levels stayedu naltered, confirming ac ell-dependent effect. [36] 
Combination Studies
Many cancers show high metabolicp lasticity,b ecause mitochondriaa re usually still functional andc an use alternative nutrientsf or energy production and biosynthesis. [37] To explore synergistic targeting of severalm etabolic pathways, the glucose uptake inhibitor glutor was combined with CB-839, [38] a small-molecule inhibitor that targetst he kidney glutaminase isoform which is overexpressed in many cancers,t os uppress the growth of HCT116 cells. [29] The combination of glutor with CB-839 decreased the GI 50 value of glutor from 428 nm (0 mm CB-839)b ya bout 40-fold to GI 50 = 10 nm (5 mm CB-839). [29] Inhibition of the glutaminase disrupts the supply of a-ketoglutarate to the TCA cycle andt herefore interferes with an alternative metabolic pathway for energy production.T he availability of the amino acid aspartate has also as trong impact on cell survival, as it influences the dependence of cell on glutamine and couldh ence offer another approachf or ac ombinatory treatment. [39] Combining chemotherapeutic agentsw ith glucose uptake inhibitors has already led to promising results. Ar easonc ould be that mostc hemotherapeutic agents elevate reactive oxygen species (ROS) levels and thereby influence redox status of the cancerc ell. [40] Treatmento fM CF-7 breast cancerc ells with WZB117 partially restored sensitivity of the cellst oward the chemotherapeutic agent adriamycin. [18j] WZB117 has also been successfully applied together with 5-fluorouracil on resistantc olon carcinomas (HCT116), which can be mostp robably explained with an observed GLUT-1 upregulation in 5-fluorouracil-resistant and-treated colon cells. [18p] The GLUT-1-selective inhibitor BAY-876 enhanced the response of cisplatin-treated esophageal squamous cell carcinomaw ith respect to cell proliferation. [25] Radiation of at umor acts through creating double-strand breaksi nD NA as well as through cellular water radiolysis, which creates ROS. [41] Hence, ac ombinatorial treatment of radiotherapy and glucose uptake inhibition might offer ap romising opportunity to target cancerm ore efficiently. An increase in GLUT-1 expression and higher glycolytic activity was observed upon radiotherapy treatment and in radiotherapy-resistant breast cancerc ells. [18l] The authors observedt hat simultaneous treatment of breast cancer cells with WZB117 sensitized the resistantc ells to radiotherapy. [18l] The simultaneous treatmento fh epatocellular carcinoma with 2DG and with kinase inhibitor sorafenib also showed promising resultsi nt argeting sorafenib-resistantp opulations in vitro and in vivo. [42] Overall,t he inhibition of glycolysis, for example, by glucose transporter inhibitors, seems to be highly effective to sensitize cancer to diverse treatment approaches.
Possible Applications beyond Oncology
Aerobic glycolysis and increased glucose dependence are also characteristic for inflammatoryd iseases (Figure 3 ). CD4 + Tcells switch from fatty acid b oxidation in the resting state to aerobic glycolysis after activation. Interestingly,G LUT-1-deficient CD4 + Tcells were unable to grow,p roliferate, survivea nd differentiate to Teffector cellsa fter activation. [2a] Tcells that upre-ChemBioChem 2020, 21,45-52 www.chembiochem.org gulate aerobic glycolysisa re involved in the establishment of inflammatory boweld isease, graft-versus-host disease and systemic lupus erythematosus. [2, 43] Notably,i ns ystemic lupus,a utoreactive CD4 + Tcells upregulate oxidative phosphorylation along with glycolysis, and combinatorialt reatment with 2DG and metformin showed promising results in mouse models. [2b] Also, HIV-infected patients hold al arge number of CD4 + Tcells, which overexpressGLUT-1. [44] Hyperplasia-associated diseases, such as psoriasis and fibrosis, exhibit uncontrolled cell proliferation and increased GLUT-1 levels, offering potential for modulation by treatment with glucose import inhibitors (Figure 3 ). [3, 45] Age-related macular degeneration (AMD)isc haracterizedbyo cular neovascularization. Because increased levels of glycolysis have been observed in endothelial cells and AMD patients exhibit increased lactate/ pyruvater atios, restriction of glycolysis might be ap romising therapeutic approach to interferew ith the endothelial proliferation. [46] Intracellular bacteria and parasites may manipulate the host cell's metabolism to increase glycolysis (Figure 3 ). The bacteria Chlamydia trachomatis, [47] Chlamydia pneumoniae, [48] Mycobacterium tuberculosis, [49] Brucella abortus [50] and Legionellap neumophila [51] have been reported to induce aW arburg-like phenotype of their host cells. Treatment with 2DG reduced the replication of L. pneumophila inside human macrophages. [51, 52] The malaria parasite Plasmodium falciparum replicates inside erythrocytes and increases GLUT-1 expression of the host cells in order to fuel its own metabolism. [53] Recently,W ei et al. successfully applied WZB117t op lasmodium-infected erythrocytes, which induced oxidative stress and apoptosis. [18e] Viral infections also lead to an adaptation of the energy metabolism of the host cells towardaerobic glycolysis. Cells infected by rhinovirus increase GLUT-1 expression and release additional glucose from their glycogen storage.T reatmentw ith glycolysis inhibitor 2DG reverts the metabolism to lipogenesis. Thus GLUT inhibitors might open an alternative opportunity to address viral infection. [54] Furthermore,t he transformation of progenitor cells to differentiatedc ells often involves as witch in the metabolic phenotype of the cell (Figure 3 ). Izumi et al. recently demonstrated that the treatment of connective tissue with 2DG drives the differentiation to tendon cells and inhibits chondrogenesis, which is associated with poor tendon healing. [55] Applying small molecules in the field of directed differentiation might offer tremendous potential.
Summary and Outlook
Aerobic glycolytic phenotypes have been observed in multiple diseases.T argeting alteredg lucoseu ptake and metabolism with appropriate tool compounds, such as GLUT inhibitors, could yield new insighti nt he diseases and pave the way for novel therapeutics trategies. Eleven distinct compound classes that inhibitg lucose uptake with sub-micromolar potency and target the glucoset ransporters with different GLUT isoform selectivity have been reported.T hese compounds have been furtherc haracterizedb iologically and provide av aluablet ool compound platform to furtheri nvestigate glucose metabolism in differentdisease models.
For less-well-characterized GLUTi soforms of class II and III, selectivet ool compounds are not yet available. As these isoforms are also overexpressed in some cancers and other diseases, [56] this field of research could offer additional opportunities for the treatment of disease.
